title: [Differentiated thyroid carcinoma: survival and prognostic factors].
abstract: OBJECTIVE
  Differentiated thyroid carcinoma (DTC) is the most common endocrine tumor. DTC has a good prognosis and survival rates higher than 85%. The aim of our study was to assess our current survival rate and to analyze prognostic factors.
  
  
  METHODS
  A retrospective analysis was conducted of 308 patients with DTC (93.5% with papillary tumors, 78.8% women). Mean age at diagnosis was 45.4±15.8years, and mean follow-up time was 8.9±6.8years. The whole group was treated and followed up using the same protocol at our hospital. The following data were collected: age at diagnosis, sex, histology, TNM stage, treatments, and date and cause of death. Survival probability was calculated using Kaplan-Meier analyses. Prognostic factors were analyzed using a univariate log rank test and a multivariate Cox regression analysis model.
  
  
  RESULTS
  Twenty-six patients died during follow-up, 15 of them (4.9%) from DTC. Thyroid carcinoma-related survival was 92.7% for the whole group. In multivariate analyses, the following parameters were associated to a significantly increased risk of death from DTC: presence of distant metastases, follicular histology, age at diagnosis older than 60years, and extrathyroid invasion.
  
  
  CONCLUSIONS
  Our survival rate is similar to that reported in literature. Assessment of prognostic factors related to an increased risk of death in our patient group, is essential to establish active therapeutic approaches in high risk patients.
authors.affiliation: Sección de Endocrinología y Nutrición, Hospital Virgen de la Salud, Complejo Hospitalario de Toledo, Toledo, España. jsastrem@sescam.jccm.es
authors.forename: Julia
authors.initials: J
authors.lastname: Sastre Marcos
authors.forename: Ofelia
authors.initials: O
authors.lastname: Llamazares Iglesias
authors.forename: Almudena
authors.initials: A
authors.lastname: Vicente Delgado
authors.forename: Amparo
authors.initials: A
authors.lastname: Marco Martínez
authors.forename: Bárbara
authors.initials: B
authors.lastname: Cánovas Gaillemin
authors.forename: Juan Luis
authors.initials: JL
authors.lastname: Orradre Romero
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Morlan López
authors.forename: José
authors.initials: J
authors.lastname: López López
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000401:mortality* / Q000628:therapy; D018249:Adenoma, Oxyphilic / Q000401:mortality / Q000628:therapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D002291:Carcinoma, Papillary / Q000401:mortality* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013964:Thyroid Neoplasms / Q000401:mortality* / Q000628:therapy; D013965:Thyroidectomy
chemical_list: D007457:Iodine Radioisotopes